KRAS and neoplasm: The study NCT03948763 combine the immune checkpoint inhibitor pembrolizumab, with a lipidic nanoformulation containing mRNA of the most frequent mutations of the oncogene KRAS, that after internalization by APCs induce T-lymphocytes that specifically target and destroy tumor cells harboring this KRAS mutations.